Collegium Pharmaceutical , Inc. (NASDAQ:COLL) director Garen G. Bohlin has recently engaged in significant stock transactions, according to a new SEC filing. On May 14, 2024, Bohlin sold 28,985 shares of common stock at weighted average prices ranging from $32.00 to $32.80, accumulating over $936,311 in total sales.
The transactions included both the acquisition and disposition of shares. Bohlin acquired the same number of shares through the exercise of options at a price of $5.73 per share, amounting to a total of $166,084. Following these transactions, Bohlin’s direct ownership in the company decreased to 44,775 shares of common stock.
Additionally, on May 16, 2024, Bohlin was granted 7,693 restricted stock units (RSUs), which represent a contingent right to receive shares of Collegium Pharmaceutical's common stock. These RSUs are set to vest on May 16, 2025, provided Bohlin continues his service with the company.
Investors and market watchers often look to the buying and selling activity of company insiders like directors for signals about the firm's financial health and future prospects. The recent transactions by Bohlin may thus be of interest to current and potential shareholders of Collegium Pharmaceutical.
InvestingPro Insights
As Collegium Pharmaceutical, Inc. (NASDAQ:COLL) navigates through the market, investors are keeping a keen eye on insider activities and broader financial metrics that could signal the company's trajectory. A recent SEC filing revealed noteworthy stock transactions by director Garen G. Bohlin, but what else should investors consider?
An InvestingPro Tip highlights that management has been aggressively buying back shares, a move often interpreted as a sign of confidence in the company's value and prospects. This aligns with another tip indicating a high shareholder yield, which combines dividend payments and share repurchases to measure how much a company returns to its shareholders. Given that Bohlin's transactions involved significant stock sales and option exercises, these tips are particularly relevant for investors assessing the impact of insider trades on their investment decisions.
Turning to real-time data from InvestingPro, Collegium Pharmaceutical's market cap stands at a solid $1.1 billion. The company's Price/Earnings (P/E) ratio of 11.95, adjusted to 11.39 for the last twelve months as of Q1 2024, suggests a potentially attractive valuation relative to earnings. Moreover, the company has shown a robust gross profit margin of 86.08% in the same period, indicating efficient cost management relative to its revenue.
Investors considering Collegium Pharmaceutical as a potential addition to their portfolio can find additional insights and tips on InvestingPro. With 11 more tips available, including predictions about net income growth and profitability, the platform offers a comprehensive analysis for those seeking to make informed decisions. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription for even deeper insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.